What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus
-
Published:2020-10-19
Issue:1
Volume:90
Page:49-56
-
ISSN:0033-3190
-
Container-title:Psychotherapy and Psychosomatics
-
language:en
-
Short-container-title:Psychother Psychosom
Author:
Evers Andrea W.M.ORCID, Colloca Luana, Blease Charlotte, Gaab Jens, Jensen Karin B., Atlas Lauren Y., Beedie Chris J., Benedetti Fabrizio, Bingel Ulrike, Büchel Christian, Bussemaker Jet, Colagiuri Ben, Crum Alia J., Finniss Damien G., Geers Andrew L., Howick Jeremy, Klinger Regine, Meeuwis Stefanie H.ORCID, Meissner Karin, Napadow Vitaly, Petrie Keith J., Rief WinfriedORCID, Smeets Ionica, Wager Tor D., Wanigasekera Vishvarani, Vase Lene, Kelley John M., Kirsch Irving,
Abstract
<b><i>Introduction:</i></b> Clinical and laboratory studies demonstrate that placebo and nocebo effects influence various symptoms and conditions after the administration of both inert and active treatments. <b><i>Objective:</i></b> There is an increasing need for up-to-date recommendations on how to inform patients about placebo and nocebo effects in clinical practice and train clinicians how to disclose this information. <b><i>Methods:</i></b> Based on previous clinical recommendations concerning placebo and nocebo effects, a 3-step, invitation-only Delphi study was conducted among an interdisciplinary group of internationally recognized experts. The study consisted of open- and closed-ended survey questions followed by a final expert meeting. The surveys were subdivided into 3 parts: (1) informing patients about placebo effects, (2) informing patients about nocebo effects, and (3) training clinicians how to communicate this information to the patients. <b><i>Results:</i></b> There was consensus that communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities. <b><i>Conclusions:</i></b> The current 3-step Delphi study provides consensus-based recommendations and practical considerations for disclosures about placebo and nocebo effects in clinical practice. Future research is needed on how to optimally tailor information to specific clinical conditions and patients’ needs, and on developing standardized disclosure training modules for clinicians.
Subject
Psychiatry and Mental health,Applied Psychology,Clinical Psychology,General Medicine
Reference68 articles.
1. Damien J, Colloca L, Bellei-Rodriguez CE, Marchand S. Pain modulation: from conditioned pain modulation to placebo and nocebo effects in experimental and clinical pain. Int Rev Neurobiol. 2018;139:255–96. 2. Petrie KJ, Rief W. Psychobiological mechanisms of placebo and nocebo effects: pathways to improve treatments and reduce side effects. Annu Rev Psychol. 2019 Jan;70(1):599–625. 3. Tekampe J, van Middendorp H, Meeuwis SH, van Leusden JW, Pacheco-López G, Hermus AR, et al. Conditioning immune and endocrine parameters in humans: a systematic review. Psychother Psychosom. 2017;86(2):99–107. 4. Chavarria V, Vian J, Pereira C, Data-Franco J, Fernandes BS, Berk M, et al. The placebo and nocebo phenomena: their clinical management and impact on treatment outcomes. Clin Ther. 2017 Mar;39(3):477–86. 5. Colagiuri B, Schenk LA, Kessler MD, Dorsey SG, Colloca L. The placebo effect: from concepts to genes. Neuroscience. 2015 Oct;307:171–90.
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|